Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although the deleterious vasoconstrictive effects of cell-free, hemoglobin-based blood substitutes have been appreciated, the systemic effects of chronic hemolysis on nitric oxide bioavailability have not been considered or quantified. Central to this investigation is the understanding that nitric oxide reacts at least 1,000 times more rapidly with free hemoglobin solutions than with erythrocytes. We hypothesized that decompartmentalization of hemoglobin into plasma would divert nitric oxide from homeostatic vascular function. We demonstrate here that plasma from patients with sickle-cell disease contains cell-free ferrous hemoglobin, which stoichiometrically consumes micromolar quantities of nitric oxide and abrogates forearm blood flow responses to nitric oxide donor infusions. Therapies that inactivate plasma hemoglobin by oxidation or nitric oxide ligation restore nitric oxide bioavailability. Decompartmentalization of hemoglobin and subsequent dioxygenation of nitric oxide may explain the vascular complications shared by acute and chronic hemolytic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [59]
In the citing paper
“In these complications HbF has a less obvious beneficial effect, perhaps because only a small number of lysed sickle erythrocytes are needed to trigger these subphenotypes.59”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [59]
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [59]
In the citing paper
“A further consequence of sickling of cells is increased RBC hemolysis. Hemolysis affects not only the number of circulating RBCs but also release of Hb (and other cytoplasmic proteins) within the blood stream, thus profoundly affecting the viscosity and colloid properties of plasma and increasing systemic NO scavenging (71, 152).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [152]
In the citing paper
“For example, in hemolytic anemia, release of free Hb may lead to systemic NO scavenging, affecting vascular tone (71, 152).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [152]
Citations
Cites
De Caterina, R., Libby, P., Peng, H. B., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M. A., Shin, W. S., & Liao, J. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118074 · Cited by 1,782
Identification of the haemoglobin scavenger receptor
Kristiansen, M., Graversen, J. H., Jacobsen, C., Sonne, O., Hoffman, H.-J., Law, S. K. A., & Moestrup, S. K. (2001) · Nature · doi:10.1038/35051594 · Cited by 1,712
Mechanism of NO-induced oxidation of myoglobin and hemoglobin
Eich, R. F., Li, T., Lemon, D. D., Doherty, D. H., Curry, S. R., Aitken, J. F., Mathews, A. J., Johnson, K. A., Smith, R. D., Phillips, et al. (1996) · Biochemistry · doi:10.1021/bi960442g · Cited by 613
Diffusion-limited reaction of free nitric oxide with erythrocytes
Liu, X., Miller, M. J. S., Joshi, M. S., Sadowska-Krowicka, H., Clark, D. A., & Lancaster, J. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.18709 · Cited by 512
A Tutorial on the Diffusibility and Reactivity of Free Nitric Oxide
Lancaster, J. R. (1997) · Nitric Oxide · doi:10.1006/niox.1996.0112 · Cited by 495
Nitric oxide in the human respiratory cycle
McMahon, T. J., Moon, R. E., Luschinger, B. P., Carraway, M. S., Stone, A. E., Stolp, B. W., Gow, A. J., Pawloski, J. R., Watke, P., Singel, D. J., et al. (2002) · Nature Medicine · doi:10.1038/nm718 · Cited by 469
Gladwin, M. T., Shelhamer, J. H., Schechter, A. N., Pease-Fye, M. E., Waclawiw, M. A., Panza, J. A., Ognibene, F. P., & Cannon, R. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11482 · Cited by 441
Self-citationRate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin
Doherty, D. H., Doyle, M. P., Curry, S. R., Vali, R. J., Fattor, T. J., Olson, J. S., & Lemon, D. D. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-672 · Cited by 432
Autoxidation kinetics of aqueous nitric oxide
Ford, P. C., Wink, D. A., & Stanbury, D. M. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81748-o · Cited by 419
Research works printed but not linked: 3
- Vaughn, M.W., Kuo, L. & Liao, J.C. Effective diffusion distance of nitric oxide in the microcirculation. Am. J. Physiol. 274, H1705–H1714 (1998).
- Vogel, W.M., Dennis, R.C., Cassidy, G., Apstein, C.S. & Valeri, C.R. Coronary constrictor effect of stroma-free hemoglobin solutions. Am. J. Physiol. 251, H413–H420 (1986).
- Pohl, U. & Lamontagne, D. Impaired tissue perfusion after inhibition of endothelium-derived nitric oxide. Basic Res. Cardiol. 86, 97–105 (1991).
Cited by
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationUpdated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Self-citationNitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation
Cosby, K., Partovi, K. S., Crawford, J. H., Patel, R. P., Reiter, C. D., Martyr, S., Yang, B. K., Waclawiw, M. A., Zalos, G., Xu, X., et al. (2003) · Nature Medicine · doi:10.1038/nm954 · Cited by 1,807
“Therapeutic application of nitrite should result in selective vasodilation to hypoxemic tissue, and could be used to treat diseases associated with ischemic tissue, neonatal pulmonary hypertension and hemolytic conditions such as sickle-cell disease, where free hemoglobin released during hemolysis scavenges NO and dis…”
BackgroundSelf-citationRother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationGuidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Mechanisms of Cell Protection by Heme Oxygenase-1
Gozzelino, R., Jeney, V., & Soares, M. P. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105600 · Cited by 1,241
“This reaction can have two pathological consequences: (a) reduction of NO bioavailability (161) and (b) Hb oxidation into ferric (Fe3+) Hb, that is, methemoglobin (162, 163), with subsequent release of heme.”
BackgroundKato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationStuart, M. J., & Nagel, R. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17192-4 · Cited by 819
Free heme toxicity and its detoxification systems in human
Kumar, S., & Bandyopadhyay, U. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.03.004 · Cited by 852
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Self-citationMechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Morris, C. R. (2005) · JAMA · doi:10.1001/jama.294.1.81 · Cited by 763
Schaer, D. J., Buehler, P. W., Alayash, A. I., Belcher, J. D., & Vercellotti, G. M. (2013) · Blood · doi:10.1182/blood-2012-11-451229 · Cited by 754
Intravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Self-citationBelcher, J. D., Chen, C., Nguyen, J., Milbauer, L., Abdulla, F., Alayash, A. I., Smith, A., Nath, K. A., Hebbel, R. P., & Vercellotti, G. M. (2014) · Blood · doi:10.1182/blood-2013-04-495887 · Cited by 695
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Kato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661
Self-citationDaily Assessment of Pain in Adults with Sickle Cell Disease
Smith, W. R., Penberthy, L. T., Bovbjerg, V. E., McClish, D. K., Roberts, J. D., Dahman, B., Aisiku, I. P., Levenson, J. L., & Roseff, S. D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00004 · Cited by 648
Arginine Metabolism: Boundaries of Our Knowledge
Morris, S. M. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.6.1602s · Cited by 637
“] Overall, the reduced plasma levels of arginine, together with increased plasma levels of cell-free hemoglobin (which acts as a trap for NO) (86), result in NO insufficiency, consistent with the increased incidence of pulmonary hypertension in sickle cell patients.”
BackgroundHillmen, P., Muus, P., Dührsen, U., Risitano, A. M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-095646 · Cited by 579
Malaria biology and disease pathogenesis: insights for new treatments
Miller, L. H., Ackerman, H. C., Su, X.-Z., & Wellems, T. E. (2013) · Nature Medicine · doi:10.1038/nm.3073 · Cited by 582
Donadee, C., Raat, N. J. H., Kanias, T., Tejero, J., Lee, J. S., Kelley, E. E., Zhao, X., Liu, C., Reynolds, H., Azarov, I., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.008698 · Cited by 572
Self-citationRed blood cells express a functional endothelial nitric oxide synthase
Kleinbongard, P. (2006) · Blood · doi:10.1182/blood-2005-10-3992 · Cited by 568
Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria
Pamplona, A., Ferreira, A., Balla, J., Jeney, V., Balla, G., Epiphanio, S., Chora, Â., Rodrigues, C. D., Gregoire, I. P., Cunha-Rodrigues, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1586 · Cited by 560
“Other researchers have shown that, as in other hemolytic diseases (for example, sickle cell anemi”
Shet, A. S., Aras, O., Gupta, K., Hass, M. J., Rausch, D. J., Saba, N., Koopmeiners, L., Key, N. S., & Hebbel, R. P. (2003) · Blood · doi:10.1182/blood-2003-03-0693 · Cited by 539
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Pulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Self-citationRed Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia
Kuhn, V., Diederich, L., Keller, T. C. S., Kramer, C. M., Lückstädt, W., Panknin, C., Suvorava, T., Isakson, B. E., Kelm, M., & Cortese-Krott, M. M. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6954 · Cited by 469
“For example, in hemolytic anemia, release of free Hb may lead to systemic NO scavenging, affecting vascular tone (71, 152).”
The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy
HEBBEL, R. P., OSAROGIAGBON, R., & KAUL, D. (2004) · Microcirculation · doi:10.1080/10739680490278402 · Cited by 463
“NO deficiency could result from several processes, including consumption by plasma hemoglobin (142); consumption from excessive superoxide generation accompanying reperfusion injury (96,134) or activation of vessel wall xanthine oxidase (9); activity of myeloperoxidase accompanying inflammatory cells (2); or even oxid…”
BackgroundSickle cell disease: old discoveries, new concepts, and future promise
Frenette, P. S., & Atweh, G. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30920 · Cited by 400
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396
Inhaled Nitric Oxide Therapy in Adults
Griffiths, M. J. D., & Evans, T. W. (2005) · New England Journal of Medicine · doi:10.1056/nejmra051884 · Cited by 398
Villagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2007) · Blood · doi:10.1182/blood-2006-12-061697 · Cited by 384
Self-citationThe biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation
Gladwin, M. T., Crawford, J. H., & Patel, R. P. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.11.032 · Cited by 378
Self-citationThe role of the nitric oxide pathway in brain injury and its treatment — From bench to bedside
Garry, P. S., Ezra, M., Rowland, M. J., Westbrook, J., & Pattinson, K. T. S. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2014.10.017 · Cited by 380
“This is thought to be secondary to destruction of NOS function by haemoglobin (Tanishima, 1980; Reiter et al., 2002; Pluta, 2008).”
BackgroundHeme on innate immunity and inflammation
Dutra, F. F., & Bozza, M. T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00115 · Cited by 351
Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease
Chen, G., Zhang, D., Fuchs, T. A., Manwani, D., Wagner, D. D., & Frenette, P. S. (2014) · Blood · doi:10.1182/blood-2013-10-529982 · Cited by 354
“Hemolysis releases cell-free hemoglobin and heme in the circulation of patients with hemoglobinopathies.(1) Cell-free hemoglobin has been shown to contribute to SCD severity by increasing oxidative stress and limiting nitric oxide bioavailability.”
BackgroundInfluentialErythrocytes are the major intravascular storage sites of nitrite in human blood
Dejam, A. (2005) · Blood · doi:10.1182/blood-2005-02-0567 · Cited by 350
Kato, G. J., Hebbel, R. P., Steinberg, M. H., & Gladwin, M. T. (2009) · American Journal of Hematology · doi:10.1002/ajh.21475 · Cited by 349
“Intravascular hemolysis releases hemoglobin into plasma, which will then potently scavenge NO via a dioxygenation reaction with oxyhemoglobin that converts NO to nitrate [11,39].”
BackgroundSelf-citationSickle Hemoglobin Confers Tolerance to Plasmodium Infection
Ferreira, A., Marguti, I., Bechmann, I., Jeney, V., Chora, Â., Palha, N. R., Rebelo, S., Henri, A., Beuzard, Y., & Soares, M. P. (2011) · Cell · doi:10.1016/j.cell.2011.03.049 · Cited by 340
Minneci, P. C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25040 · Cited by 331
Predicting clinical severity in sickle cell anaemia
Steinberg, M. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05411.x · Cited by 321
“…features of disease, where sickle erythrocyte destruction leads to high plasma haemoglobin levels that scavenge the vasodilator, nitric oxide (NO), blunting the vasodilatory response and perhaps promoting vaso-occlusion, further hinders the measurement of disease severity (Reiter et al, 2002).”
BackgroundArginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
Morris, C. R., Morris, S. M., Hagar, W., van Warmerdam, J., Claster, S., Kepka-Lenhart, D., Machado, L., Kuypers, F. A., & Vichinsky, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-967oc · Cited by 329
“Recent studies suggest that rapid scavenging of nitric oxide by cell-free hemoglobin, which is found in high concentrations under conditions of hemolysis, may limit nitric oxide bioavailability in sickle cell disease (13), while inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin (14).”
Pulmonary Arterial Hypertension
Chin, K. M., & Rubin, L. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.024 · Cited by 309
Inflammation in sickle cell disease
Conran, N., & Belcher, J. D. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189012 · Cited by 294
“Endothelial dysfunction occurs as a consequence of endotheliumderived NO depletion by cell-free hemoglobin [56, 240], endothelial NOS uncoupling and consumption of L-arginine (the substrate for NOS) by arginase released during hemolysis [241].”
InfluentialPathophysiology and treatment of stroke in sickle-cell disease: present and future
Switzer, J. A., Hess, D. C., Nichols, F. T., & Adams, R. J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70469-0 · Cited by 309
Barabino, G. A., Platt, M. O., & Kaul, D. K. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105339 · Cited by 311
No scavenging and the hypertensive effect of hemoglobin-based blood substitutes
Olson, J. S., Foley, E. W., Rogge, C., Tsai, A.-L., Doyle, M. P., & Lemon, D. D. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.11.030 · Cited by 308
Unraveling the Reactions of Nitric Oxide, Nitrite, and Hemoglobin in Physiology and Therapeutics
Kim-Shapiro, D. B., Schechter, A. N., & Gladwin, M. T. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204350.44226.9a · Cited by 308
Self-citationSteinberg, M. H. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.157 · Cited by 293
“Plasma hemoglobin and the liberation of erythrocyte arginase into the circulation could be the driving force behind some complications of sickle cell disease because of their effect on nitric oxide (NO) bioavailability[63,64].”
BackgroundOxygen therapeutics: can we tame haemoglobin?
Alayash, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1307 · Cited by 303
“These small quantities of Hb limit NO availability and contribute to the vasoconstrictive effects seen in sickle cell patient”
BackgroundPulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298
“…2006 The Authors 112 Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 134, 109–115 intravascular haemolysis and scavenging of nitric oxide (NO) by cell-free plasma haemoglobin (Aslan et al, 2001; Reiter et al, 2002; Jison & Gladwin, 2003; Gladwin et al, 2004).”
BackgroundYeo, T. W., Lampah, D. A., Gitawati, R., Tjitra, E., Kenangalem, E., McNeil, Y. R., Darcy, C. J., Granger, D. L., Weinberg, J. B., Lopansri, B. K., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070819 · Cited by 299
Beleslin-Cokic, B. B., Cokic, V. P., Yu, X., Weksler, B. B., Schechter, A. N., & Noguchi, C. T. (2004) · Blood · doi:10.1182/blood-2004-02-0744 · Cited by 289
Self-citationWalter, P. B., Fung, E. B., Killilea, D. W., Jiang, Q., Hudes, M., Madden, J., Porter, J., Evans, P., Vichinsky, E., & Harmatz, P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06277.x · Cited by 288
“These increased oxidants and intravascular haemoglobin from haemolysis (Reiter et al, 2002) may contribute to the consumption of nitric oxide in SCD (Aslan et al, 2001).”
BackgroundNitric oxide's reactions with hemoglobin: a view through the SNO-storm
Gladwin, M. T., Lancaster, J. R., Freeman, B. A., & Schechter, A. N. (2003) · Nature Medicine · doi:10.1038/nm0503-496 · Cited by 291
“Further support for the primacy of diffusional barriers in regulating vascular NO signaling comes from a recent study of the chronic hemolysis experienced by patients with sickle-cell diseas”
BackgroundSelf-citationSanchez, A., Lukwiya, M., Bausch, D., Mahanty, S., Sanchez, A. J., Wagoner, K. D., & Rollin, P. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10370-10377.2004 · Cited by 281
“If reduction of blood NO or its effects can lessen patient stress, then the administration of scavenging compounds (25, 26, 27) and/or vasoconstrictors (catecholamines or epinephrine/norepinephrine) could be a useful treatment for sustaining patients through critical periods of Ebola virus infection.”
BackgroundSchaer, D. J., Vinchi, F., Ingoglia, G., Tolosano, E., & Buehler, P. W. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00415 · Cited by 268
Baek, J. H., D’Agnillo, F., Vallelian, F., Pereira, C. P., Williams, M. C., Jia, Y., Schaer, D. J., & Buehler, P. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59770 · Cited by 280
“In our model, Hb-dependent NO consumption by plasma from animals transfused with old blood conforms to the most extensively investigated concept of hemolysis mediated vascular dysfunction (13, 14).”
Cardiovascular Abnormalities in Sickle Cell Disease
Gladwin, M. T., & Sachdev, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.900 · Cited by 276
Self-citationDivergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease
Gladwin, M. T., Schechter, A. N., Ognibene, F. P., Coles, W. A., Reiter, C. D., Schenke, W. H., Csako, G., Waclawiw, M. A., Panza, J. A., & Cannon, R. O. (2003) · Circulation · doi:10.1161/01.cir.0000044943.12533.a8 · Cited by 273
Self-citationPulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease
Fonseca, G. H. H., Souza, R., Salemi, V. M. C., Jardim, C. V. P., & Gualandro, S. F. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00134410 · Cited by 274
Storage lesion: role of red blood cell breakdown
Kim‐Shapiro, D. B., Lee, J., & Gladwin, M. T. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03100.x · Cited by 271
“NOS uncoupling results in formation of superoxide from the NOS rather than NO.”
BackgroundMethodSelf-citationPathogenic mechanisms of pulmonary arterial hypertension
Chan, S. Y., & Loscalzo, J. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.09.006 · Cited by 265
“Hemolysis accompanying these disorders may lead to destruction of bioactive nitric oxide by free hemoglobin [81] or reactive oxygen species [82,83].”
BackgroundHeme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice
Belcher, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26857 · Cited by 265
Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
Moyo, V. M., Mukhina, G. L., Garrett, E. S., & Brodsky, R. A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04992.x · Cited by 264
“…and oesophageal spasm is not entirely understood; however, as in 136 ª 2004 Blackwell Publishing Ltd, British Journal of Haematology, 126, 133–138 sickle cell anaemia, it is likely that free haemoglobin resulting from intravascular haemolysis depletes tissue nitric oxide (Reiter et al, 2002).”
BackgroundCamus, S. M., De Moraes, J. A., Bonnin, P., Abbyad, P., Le Jeune, S., Lionnet, F., Loufrani, L., Grimaud, L., Lambry, J.-C., Charue, D., et al. (2015) · Blood · doi:10.1182/blood-2014-07-589283 · Cited by 262
“Met-Hb releases heme readily from its prosthetic pocket and this is enhanced by repeated cycles of deoxygenation and polymerization.(3,47) Heme, released from Hb, is lipophilic and highly membranotropic.”
Hsu, L. L., Champion, H. C., Campbell-Lee, S. A., Bivalacqua, T. J., Manci, E. A., Diwan, B. A., Schimel, D. M., Cochard, A. E., Wang, X., Schechter, A. N., et al. (2007) · Blood · doi:10.1182/blood-2006-08-039438 · Cited by 263
Self-citationThe chemical biology of S-nitrosothiols
Broniowska, K. A., & Hogg, N. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4590 · Cited by 259
Self-citationNur, E., Biemond, B. J., Otten, H., Brandjes, D. P., Schnog, J. B., & the CURAMA Study Group (2011) · American Journal of Hematology · doi:10.1002/ajh.22012 · Cited by 248
“As a result of continuous intravascular hemolysis, sickle cell patients have highly increased plasma levels of cell-free hemoglobin [13,23].”
BackgroundMachado, R. F., Barst, R. J., Yovetich, N. A., Hassell, K. L., Kato, G. J., Gordeuk, V. R., Gibbs, J. S. R., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306167 · Cited by 250
Self-citationSickle cell disease vasculopathy: A state of nitric oxide resistance
Wood, K. C., Hsu, L. L., & Gladwin, M. T. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.01.008 · Cited by 246
“, L-NMMA) are blunted and nearly abolished to NO donors (sodium nitroprusside) in patients with SCD and high concentrations of hemoglobin, especially in males, suggesting estrogenic effects on NO synthase expression and activity [43,44].”
BackgroundInfluentialSelf-citationHemoglobin and the Paracrine and Endocrine Functions of Nitric Oxide
Schechter, A. N., & Gladwin, M. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmcibr023045 · Cited by 251
Self-citationThe role of blood rheology in sickle cell disease
Connes, P., Alexy, T., Detterich, J., Romana, M., Hardy-Dessources, M.-D., & Ballas, S. K. (2016) · Blood Reviews · doi:10.1016/j.blre.2015.08.005 · Cited by 225
“In support of these mechanisms, plasma from patients with SCA contains cell-free ferrous oxyhemoglobin, which stoichiometrically consumes micromolar quantities of NO and abrogates forearm blood flow response to NO donor infusion [40].”
BackgroundMechanism of endothelial dysfunction in chronic kidney disease
Malyszko, J. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.06.019 · Cited by 237
Ataga, K. I., Smith, W. R., De Castro, L. M., Swerdlow, P., Saunthararajah, Y., Castro, O., Vichinsky, E., Kutlar, A., Orringer, E. P., Rigdon, G. C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-110098 · Cited by 235
“Mean age, y (range) 33.6 (19-55) 37.2 (20-58) 35.7 ( 21-60 ) .375 Mean weight, kg (range) 69.2 (48-125) 69.9 (49-109) 66.9 (39-114) .732 Hospitalizations due to painful episodes in previous 12 mo*, no. (%) None 6 (20) 5 (17) 12 (39) .433 1 11 (37) 5 (17) 6 (19) — 2 to 3 7 (23) 9 (31) 6 (19) — More than 3 6 (20) 9 (31)…”
InfluentialNouraie, M., Lee, J. S., Zhang, Y., Kanias, T., Zhao, X., Xiong, Z., Oriss, T. B., Zeng, Q., Kato, G. J., Gibbs, J. S. R., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.068965 · Cited by 226
Self-citationAcute Kidney Injury after Cardiac Surgery: Prediction, Prevention, and Management
Cheruku, S. R., Raphael, J., Neyra, J. A., & Fox, A. A. (2023) · Anesthesiology · doi:10.1097/aln.0000000000004734 · Cited by 193
Gladwin, M. T. (2011) · JAMA · doi:10.1001/jama.2011.235 · Cited by 222
Self-citationEmerging role of nitrite in human biology
Dejam, A., Hunter, C. J., Schechter, A. N., & Gladwin, M. T. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.02.002 · Cited by 221
Self-citationAl-Tonbary, Y., Tricta, F., El-Beshlawy, A., Badr, M. A., & Mansour, A. (2013) · The Scientific World Journal · doi:10.1155/2013/912913 · Cited by 221
Jison, M. L., Munson, P. J., Barb, J. J., Suffredini, A. F., Talwar, S., Logun, C., Raghavachari, N., Beigel, J. H., Shelhamer, J. H., Danner, R. L., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2760 · Cited by 221
Self-citationHemolysis-associated priapism in sickle cell disease
Nolan, V. G., Wyszynski, D. F., Farrer, L. A., & Steinberg, M. H. (2005) · Blood · doi:10.1182/blood-2005-04-1594 · Cited by 215
Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria
Gramaglia, I., Sobolewski, P., Meays, D., Contreras, R., Nolan, J. P., Frangos, J. A., Intaglietta, M., & van der Heyde, H. C. (2006) · Nature Medicine · doi:10.1038/nm1499 · Cited by 215
“Thus, we posit that low NO bioavailability exacerbates underlying pathogenic processes, as observed in sickle cell diseas”
BackgroundSustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
Hill, A., Hillmen, P., Richards, S. J., Elebute, D., Marsh, J. C., Chan, J., Mojcik, C. F., & Rother, R. P. (2005) · Blood · doi:10.1182/blood-2005-02-0564 · Cited by 212
Huertas, A., Guignabert, C., Barberà, J. A., Bärtsch, P., Bhattacharya, J., Bhattacharya, S., Bonsignore, M. R., Dewachter, L., Dinh-Xuan, A. T., Dorfmüller, P., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00745-2017 · Cited by 205
Self-citationKato, G. J., Martyr, S., Blackwelder, W. C., Nichols, J. S., Coles, W. A., Hunter, L. A., Brennan, M., Hazen, S. L., & Gladwin, M. T. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05701.x · Cited by 207
“…Belhassen et al, 2001; Eberhardt et al, 2003; Gladwin et al, 2003), due in large part to the consumption of NO by cell-free plasma haemoglobin (Reiter et al, 2002) and reactive oxygen species (Aslan et al, 2000, 2001, 2003; Aslan & Freeman, 2004), and compounded by low levels of the substrate…”
BackgroundResultSelf-citationSildenafil therapy in patients with sickle cell disease and pulmonary hypertension
Machado, R. F., Martyr, S., Kato, G. J., Barst, R. J., Anthi, A., Robinson, M. R., Hunter, L., Coles, W., Nichols, J., Hunter, C., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05625.x · Cited by 212
“…haemolytic disorders), a haemolysis-associated endothelial dysfunction is caused by the release of erythrocyte haemoglobin, which scavenges NO (Reiter et al, 2002), and of erythrocyte arginase, which metabolises l-arginine, the substrate for NO synthesis (Belfiore, 1964; Azizi et al, 1970;…”
BackgroundSelf-citationMechanisms of haemolysis-induced kidney injury
Van Avondt, K., Nur, E., & Zeerleder, S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0181-0 · Cited by 204
Sickle Red Cell–Endothelium Interactions
KAUL, D. K., FINNEGAN, E., & BARABINO, G. A. (2009) · Microcirculation · doi:10.1080/10739680802279394 · Cited by 208
“Because of the anti-inflammatory properties of NO, NO supplementation may be of therapeutic value, since NO is effectively inactivated by cell-free plasma heme and excessive oxidant generation in sickle cell disease [48,63].”
BackgroundThe Red Blood Cell—Inflammation Vicious Circle in Sickle Cell Disease
Nader, E., Romana, M., & Connes, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00454 · Cited by 192
“Blood flow responses to sodium nitroprusside (a NO donor) or to L-NMMA (a NO-synthase inhibitor) are abolished in patients with SCD (17).”
BackgroundA central role for free heme in the pathogenesis of severe malaria: the missing link?
Ferreira, A., Balla, J., Jeney, V., Balla, G., & Soares, M. P. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0368-5 · Cited by 205
“In addition, cell-free Hb also acts as a potent NO scavenger, an effect that reduces NO bioavailability [9, 92].”
BackgroundPulmonary hypertension and nitric oxide depletion in sickle cell disease
Bunn, H. F., Nathan, D. G., Dover, G. J., Hebbel, R. P., Platt, O. S., Rosse, W. F., & Ware, R. E. (2010) · Blood · doi:10.1182/blood-2010-02-268193 · Cited by 202
Ye, Z., Smith, C., & Kullo, I. J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.12.023 · Cited by 200
Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia
Morris, C. R. (2008) · Hematology · doi:10.1182/asheducation-2008.1.177 · Cited by 194
“A new disease paradigm involving hemolysis-associated endothelial dysfunction7,8 has implication for SCD,7,9 thalassemia,10 and all hemolytic conditions.8 The process of hemolysis initiates a global attack on the arginine-NO pathway.8,11 Under normal conditions, hemoglobin is safely packaged within the erythrocyte pla…”
BackgroundInfluential
Metadata
- Authors
- Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T.
- Affiliations
- National Institutes of Health (US)
- Medical College of Wisconsin (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Nature Medicine
- Published
- 2002-11-11
- Volume
- 8
- Issue
- 12
- Pages
- 1383-1389
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241694836
- Semantic Scholar
- 80bbf9611dbe14c7276b2a4dbca6e42007866746
- Cited by
- 1,330
- References
- 45
- Citations by year
- 2026: 44 · 2025: 39 · 2024: 45 · 2023: 39 · 2022: 57 · 2021: 55 · 2020: 56 · 2019: 59 · 2018: 60 · 2017: 45 · 2016: 62 · 2015: 63 · 2014: 69 · 2013: 68 · 2012: 68
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM55792)
- National Center for Research Resources (P41RR001008, RR 01008)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- free hemoglobin, nitric oxide bioavailability, sickle cell disease, chronic hemolysis, plasma hemoglobin, forearm blood flow, hemoglobin oxidation, vasoconstriction
- MeSH terms
- Adult, Anemia, Sickle Cell, Biological Availability, Heme, Hemocyanins, Hemoglobins, Hemolysis, Humans, Middle Aged, Nitric Oxide, Oxidation-Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.